Literature DB >> 9632123

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.

C Seifarth1, J Bergmann, J J Holst, R Ritzel, W Schmiegel, M A Nauck.   

Abstract

GLP-1, an incretin hormone of the enteroinsular axis with insulinotropic and glucagonostatic activity, is secreted after nutrient ingestion. GLP-1 is mainly produced by intestinal L-cells in the lower gastrointestinal tract (GIT); simple carbohydrates are absorbed in the upper GIT and alpha-glucosidase inhibition leads to augmented and prolonged GLP-1 release in normal subjects. In a cross-over study, 100 mg acarbose or placebo was administered simultaneously with 100 g sucrose to 11 hyperglycaemic Type 2 diabetic patients poorly controlled with diet and sulphonylureas. Plasma levels of GLP-1, insulin, C-peptide, glugacon, GIP, glucose and H2-exhalation were measured over 6 h. Differences in the integrated responses over the observation period were evaluated by repeated measurement analysis of variance with fasting values used as covariates. With acarbose, sucrose reached the colon 60-90 min after ingestion as indicated by a significant increment in breath hydrogen exhalation (p = 0.005). After an early GLP-1 increment 15 min after sucrose under both conditions, GLP-1 release was prolonged in the acarbose group (p = 0.001; significant from 210 to 360 min.). Initially (0-150 min), glucose (p = 0.001), insulin (p = 0.001), and GIP (p < 0.001) were suppressed by acarbose, whereas later there were no significant differences. Glucagon levels were higher with acarbose in the last 3 h of the 6 h observation period (p = 0.02). We conclude that in hyperglycaemic Type 2 diabetic patients, ingestion of acarbose with a sucrose load leads to elevated and prolonged GLP-1 release.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632123     DOI: 10.1002/(SICI)1096-9136(199806)15:6<485::AID-DIA610>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  29 in total

1.  Acarbose improves hypoglycaemia following gastric bypass surgery without increasing glucagon-like peptide 1 levels.

Authors:  Juan Patricio Valderas; Jessica Ahuad; Lorena Rubio; Manuel Escalona; Felipe Pollak; Alberto Maiz
Journal:  Obes Surg       Date:  2012-04       Impact factor: 4.129

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 3.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Authors:  M A Nauck; I Vardarli; C F Deacon; J J Holst; J J Meier
Journal:  Diabetologia       Date:  2010-09-25       Impact factor: 10.122

Review 4.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

5.  OGTT-derived measures of insulin sensitivity are confounded by factors other than insulin sensitivity itself.

Authors:  Katrin Hücking; Richard M Watanabe; Darko Stefanovski; Richard N Bergman
Journal:  Obesity (Silver Spring)       Date:  2008-07-10       Impact factor: 5.002

6.  Hypoglycemic and hypolipidemic effects of Saururus chinensis Baill in streptozotocin-induced diabetic rats.

Authors:  Ji-Yeon Hwang; Jian Zhang; Min-Jung Kang; Soo-Kyung Lee; Hyun-A Kim; Jong-Jin Kim; Jung-In Kim
Journal:  Nutr Res Pract       Date:  2007-06-30       Impact factor: 1.926

Review 7.  Cardiovascular risk stratification and management in pre-diabetes.

Authors:  Kristine Færch; Dorte Vistisen; Nanna Borup Johansen; Marit Eika Jørgensen
Journal:  Curr Diab Rep       Date:  2014-06       Impact factor: 4.810

Review 8.  Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?

Authors:  André J Scheen
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Who should benefit from the use of alpha-glucosidase inhibitors?

Authors:  Ariane Godbout; Jean-Louis Chiasson
Journal:  Curr Diab Rep       Date:  2007-10       Impact factor: 4.810

Review 10.  New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

Authors:  Angela M Abbatecola; Stefania Maggi; Giuseppe Paolisso
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.